ES
Therapeutic Areas
Seres Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VOWST™ (SER-109) | Prevention of recurrent Clostridioides difficile infection (rCDI) | Approved |
| SER-155 | Prevention of antibiotic-resistant infections and graft-versus-host disease (GvHD) in immunocompromised patients | Phase 1b |
| SER-301 | Ulcerative Colitis | Phase 1b |
| SER-287 | Ulcerative Colitis | Phase 2b |
| SER-401 | Metastatic melanoma (in combination with nivolumab) | Phase 1b |
Leadership Team at Seres Therapeutics
ED
Eric D. Shaff
President and Chief Executive Officer
LV
Lisa von Moltke, M.D.
Executive Vice President, Chief Medical Officer
TJ
Thomas J. DesRosier
Executive Vice President, Chief Legal Officer and Corporate Secretary
MR
Matthew R. Henn, Ph.D.
Chief Scientific Officer
CJ
Caroline J. Loew, Ph.D.
Former Chief Executive Officer
JG
John G. Aunins, Ph.D.
Board Member
CD
Cameron Durrant, M.D.
Board Member
BJ
Barbara J. Dalton, Ph.D.
Board Member
RP
Richard P. Shea
Board Member
KA
Katherine A. High, M.D.
Board Member